Home Categories Biochemical Engineering Olaparib (AZD2281, Ku-0059436)
A6541312

Olaparib (AZD2281, Ku-0059436) , ≥98% , 763113-22-0

CAS NO.:763113-22-0

Empirical Formula: C24H23FN4O3

Molecular Weight: 434.46

MDL number: MFCD13185161

EINECS: 642-941-5

Pack Size Price Stock Quantity
10MG RMB39.20 In Stock
25MG RMB79.20 In Stock
100MG RMB155.20 In Stock
250MG RMB221.60 In Stock
1G RMB604.80 In Stock
5G RMB1368.00 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Density  1.43
storage temp.  -20°C
solubility  Soluble in DMSO (up to 33 mg/ml) or in Ethanol (up to 1.7 mg/ml)
pka 12.07±0.40(Predicted)
form  solid
color  Off-white
Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
InChIKey FDLYAMZZIXQODN-UHFFFAOYSA-N
SMILES C1(=O)C2=C(C=CC=C2)C(CC2=CC=C(F)C(C(N3CCN(C(C4CC4)=O)CC3)=O)=C2)=NN1
CAS DataBase Reference 763113-22-0

Description and Uses

Olaparib, marketed by AstraZeneca under the brand name Lynparza , was approved in the USA in December 2014 as a targeted, single-agent therapy for the treatment of germline BRCA-mediated advanced ovarian cancer.Olaparib, originally developed by KuDOS pharmaceuticals and later by AstraZeneca, functions as a poly ADP ribose polymerase inhibitor and has been specifically approved for patients who have received three or more treatments of chemotherapy. In clinical trials, the drug prolonged progression- free survival for patients suffering from platinum-sensitive recurrent serous ovarian cancer. Olaparib is also currently in various phases of investigation for treatment of breast, gastric, prostate, pancreatic and non-small cell lung cancer.

Olaparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy.

Safety

Symbol(GHS) 
GHS05
Signal word  Danger
Hazard statements  H314
Precautionary statements  P501-P260-P264-P280-P303+P361+P353-P301+P330+P331-P363-P304+P340+P310-P305+P351+P338+P310-P405
Risk Statements  22-38-37-36
Safety Statements  24/25-37/39
HazardClass  IRRITANT
HS Code  29339900

RELATED PRODUCTS